Additionally, NKG2D-mediated killing in AA and PNH does not account for the clinical efficacy of T cell-mediated therapies and the recently demonstrated MHC class I-restriction of autoimmune attack in AA (91–94). Here, KLRK1 is linked to paroxysmal nocturnal hemoglobinuria.